Deep brain stimulation (DBS) has emerged as a powerful surgical therapy for the management of treatment-resistant movement disorders, epilepsy and neuropsychiatric disorders. Although DBS may be clinically effective in many cases, its mode of action is still elusive. It is unclear which neural cell types are involved in the mechanism of DBS, and how high-frequency stimulation of these cells may lead to alleviation of the clinical symptoms. Neurons have commonly been a main focus in the many theories explaining the working mechanism of DBS. Recent data, however, demonstrates that astrocytes may be active players in the DBS mechanism of action. In this review article, we will discuss the potential role of reactive and neurogenic astrocytes (neural progenitors) in DBS.
Introduction
The first medical use of deep brain stimulation (DBS) was by the Roman physician Scribonius Largus, who utilized the electric torpedo fish to treat arthritis and gout (Largus S 1529). It was only later with the careful expertise of Horsely 1 and a series of neurosurgeons that the clinical application of brain lesioning was explored. 1, 2 This technique was refined to include electrical stimulation, particularly of the thalamus and pallidum, in cases of movement disorders. 3 In the early 1960s, it became evident that high-frequency electrical stimulation (HFS), which was routinely used to determine the precise area of the lesion, also had beneficial effects on disease symptoms. 4 It was not until the 1970s when HFS was more routinely used as a chronic therapy to treat movement disorders, particularly those stemming from the cerebellum. 5, 6 Later in the 1990s, the technology of chronic implanted pacemakers was combined with chronic implanted deep brain electrodes, 7 and the marriage resulted in what is now known as DBS. Today, DBS has become increasingly accepted as a neuromodulatory technique in the treatment of a variety of neurological and neuropsychiatric disorders. [8] [9] [10] DBS therapy has been successfully applied for numerous medication-refractory basal ganglia disorders such as Parkinson's disease 9 and dystonia, for essential tremor, 8 and recently for epilepsy, 11 depression, 12 pain, 13 Tourette's syndrome 14 and obsessive compulsive disorder. 15 To date, the underlying mechanism of DBS in the treatment of these disorders is unknown. 16 The majority of studies are focused on the change in neuronal activity in the immediate stimulated target area (inhibition) as well as in excitation of targets and circuits. However, it is conceivable that DBS will not only affect neurons in this network, but also glial cells, and that a change in both cell types may contribute to its therapeutic effect.
Astrocytes are excellent candidates to be involved in DBS. They are known to assemble into networks of cells that can propagate calcium waves upon stimulation 17, 18 and form a tripartite synapse together with neuronal synapses and, as such, are active players in neural signaling. 18, 19 Not only can astrocytes be directly stimulated by HFS, 20 they also react to the implantation of the stimulation electrode, 21 which might lead to a change in their function. 22, 23 The presence of these reactive astrocytes in the vicinity of the implanted electrode may lead to an altered modulation of neural signaling. Furthermore, a subset of astrocytes is believed to function as neural stem cells in the adult brain 24 ,25 and brain injury may induce stem cell properties in cortical astrocytes. 26 Thus an appealing hypothesis is emerging that the effect of DBS on brain function is, at least in part, directly induced by the effect of astrocytes on neuronal networks, or by astrocyte-like neural stem cells that are capable of division and genesis of more astrocytes, neurons and oligodendrocytes in response to HFS.
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Mechanism of action of DBS
The typical therapeutic frequency range of DBS is between 80 and 185 Hz, with a stimulation current between 1 and 10 mA. 30 To develop a better understanding of how DBS changes brain function, it is essential to understand how neural networks and neural cells are affected by chronic HFS. Over the last years, many excellent reviews have discussed and surveyed the biological and theoretical data that could explain the clinical effect of DBS. [30] [31] [32] These reviews focus on neurons and describe the potential effects of HFS on myelinated and unmyelinated axons, dendrites, neuronal cell bodies and neuronal networks. We will summarize the neuronal theories and refer to extensive reviews on this topic.
Myelinated axons, neuronal cell bodies and dendrites all have different electrical properties (chronaxies), and based on these, it is likely that the standard stimulation parameters of DBS will predominantly affect axons, rather than the cell bodies or dendrites. 16 This leads to complex patterns of activity with the net result that DBS may have both excitatory 31 and inhibitory 33 effects on neuronal activity. The net inhibitory effect could be the result of indirect synaptic inhibition by retrograde activation of the incoming axons (jamming), or of neurotransmitter depletion in the outgoing axons (synaptic fatigue) due to extensive high-frequency synaptic firing. 34, 8 Furthermore, the net effect of the stimulation is also dependent on whether the stimulated axons extend from an excitatory or inhibitory neuron. 34, 8 Interestingly, the activity in the axon and the neuronal cell body can even be decoupled, 32 resulting in a hyper-polarization of the neuronal cell body and a depolarization of the axon. The overall outcome will be a silenced neuronal firing of the target structure, with an increased synaptic output of the stimulated axons near the electrodes. 30, 31 Besides the local effects of DBS on neuronal elements, it might also act on large neural networks. Behavioral changes such as anxiety reduction, or mood improvement, which are often experienced by patients within seconds following stimulation support the notion that there is a rapid, and global alteration in neural networks activity and function. More regular, and probably normalized firing rates and patterns of neurons are observed after DBS 35, 36 and the associated therapeutic benefit of DBS on Parkinson's disease 34, 37 may in fact thus be a network change. It is thought that during stimulation, the cortico-basal-ganglia-thalamo-cortical network is not restored to the pre-pathological state, but rather that HFS disrupts the pathological network activity allowing an improvement in the affected brain function. 34 Whether similar changes in network activity also underlie the therapeutic effect of DBS in neuropsychiatric diseases or epilepsy is not clear yet.
Neurobiology of DBS-the astrocyte contribution
Identifying the cell types involved in DBS is instrumental in understanding its mechanism of action. It is becoming increasingly clear that astrocytes are active players in neural communication, 38 and that an astrocytic network can modulate neuronal activity. 17, 18 Rodent astrocytes possess small somata ( < 10 mm), and numerous highly branched processes that can reach distances of up to 100 mm. 39 These processes connect to those of other astrocytes through gap junctions, 40 and enwrap neuronal synapses. 41 This intimate interaction between the astrocytes and neuronal synapses is termed the 'tripartite synapse,' 42 see Figure 1 . Moreover, astrocytes contact blood vessels and can regulate local blood flow in the brain. 43 Human astrocytes are even more complex, as they are threefold larger than rodent astrocytes, and have more and longer processes. Importantly, it is estimated that one human astrocyte interacts with up to two million synapses, making them appropriate candidates for playing an important role in modulating DBS-induced neuronal function. 44 Astrocyte signaling induced by HFS Astrocytes sense neural communication, as is evident by the expression of numerous neurotransmitter receptors on their membrane. The most predominant receptors belong to the G protein-coupled receptor family. 45, 46 It also must be considered that astrocytes can release gliotransmitters, such as glutamate, D-serine and ATP, which interact with pre-and postsynaptic receptors. 47 Furthermore, astrocytes can also be directly depolarized by HFS, leading to activated astrocytes, which release calcium from intracellular stores that can modulate synaptic transmission. 48 Astrocytes are also known to communicate with each other by Ca 2 þ waves (through hemi-channels and gap junctions), which are initiated after neuronal activation via G q G protein-coupled receptor signaling on astrocytic micro-domains (see Figure 1 ). 45 A first indication that astrocytes respond to HFS is the observation that DBS modulates the regional blood flow in the area stimulated with HFS. [49] [50] [51] This might be an indirect effect caused by neuronal stimulation, as an increase or decrease in blood flow reflects an increase or decrease in neuronal activity. 52 Nevertheless, a modulation in blood flow is a direct manifestation of a change in astrocytic activity either directly induced by DBS, 43 or as a response to the activation of a neuron or axon as a result of DBS. Furthermore, astrocytes can exhibit a rapid Ca 2 þ increase in response to electrical stimulation in vivo. Using two-photon imaging, Bekar et al. 53 investigated 100 Hz stimulation (a frequency applied for DBS in the clinic) of the ventrolateral thalamic nucleus, and found increased Ca 2 þ levels in the cortex, demonstrating for the first time in a living animal that astrocytes can react to electrical stimulation, and can modulate neural networks in this manner. Recently, Tawfik et al. 20 showed that HFS Potential role for glia in DBS effect V Vedam-Mai et al abolished spontaneous spindle oscillations in ferret brain slices and that simultaneously, the release of glutamate and adenosine increased. Subsequent treatment with the Na þ channel inhibitor tetrodotoxin led to an abolishment of spindles, but this treatment did not block glutamate release. Tawfik et al. concluded that the resultant effect is likely to be due to the release of glutamate from astrocytes, since tetrodotoxin inhibits axonal-dependent synaptic release, making a neuronal source unlikely. Furthermore, they showed that a direct HFS of primary astrocytes resulted in calcium waves and release of glutamate. This study corroborates the earlier study of Bekar et al., 53 in which they showed a Ca 2 þ -independent increase in ATP, and subsequent accumulation of adenosine in the extracellular space around the electrode. Elimination of Ca 2 þ from the extracellular space prevents a Ca 2 þ influx through voltage-gated Ca 2 þ channels upon depolarization of the membrane and, therefore, prevents neuronal synaptic release of ATP. Although astrocytes do express voltage-gated Ca 2 þ channels, it has been shown that the increase in intracellular [Ca 2 þ ] in astrocytes upon a depolarization stimulus is a glutamate-mediated response, rather than a Ca 2 þ influx through the voltage-gated Ca 2 þ channels. 54 Therefore, the finding of Bekar et al. strongly suggests that ATP is not synaptically released, and, therefore, is likely to be released by astrocytes. The mechanism by which astrocytes release ATP is still poorly understood, 47, 55 but outside the cell, ATP is rapidly converted into adenosine by ecto-ATPase. 56 Adenosine then can inhibit synaptic transmission by acting on A1 receptors, which are highly abundant in the brain. 56 Activation of postsynaptic A1 receptors opens K þ channels, 57 while pre-synaptic A1 receptors close Ca 2 þ channels. 58 Both actions will lead to an inhibition of neuronal communication.
Additionally, astrocytic Ca 2 þ waves were found to occur after stimulation, and these waves propagated away from the electrode site. Further experiments in mouse models for tremor indicate that adenosine signaling is essential to the anti-tremor effect of HFS. When the adenosine A 1 R antagonist DPCPX or the ecto-ATPase inhibitor ARL-67156 was used, the HFS-induced suppression of thalamic neuronal activity was abolished. This occurred in both homoand heterosynaptic pathways. Furthermore, it was suggested that adenosine reduced the distance of the DBS spread in the brain, thereby preventing any negative outcome of the procedure. 53 The effect of adenosine and glutamate (which could both be potentially released by astrocytes) on the therapeutic effect of DBS has been investigated in two other studies, 59 ,60 which both suggest another level of interference for these gliotransmitters in DBS. The actual surgical procedure of inserting the DBS electrode into the brain itself triggers the release of adenosine and glutamate, 60 which corresponds to the mechanical stimulation, and induces activation of calcium signaling and ATP release in cultured astrocytes. 61, 62 The astrocytic activation by DBS electrodes is thought to contribute to the microthalamotomy effect of electrode insertion. The induction of such a micro-lesion is, in some cases, enough to improve clinical symptoms. We have recently shown an improvement in postural and intention tremors upon microelectrode recording and macro-stimulation, which was used to refine the DBS lead placement in the ventral intermediate nucleus of the thalamus.
63 Figure 1 Astrocyte-neuron communication through Ca 2 þ and gliotransmitter signaling in tripartite synapse. Astrocytes (green) can directly communicate with neurons at the synapse (blue). Neurotransmitters, released by depolarized neurons, are sensed by the astrocytic Gq protein-coupled receptors (Gq-GPCRs), resulting in an increase in intracelluar Ca 2 þ , which activates gliotransmitter release. The mechanisms controlling the subsequent release of the gliotransmitters glutamate, D-serine and ATP and the direct effect of these transmitters on neurons are still not completely resolved. The Gq GPCRs activate via a phospholipase C/inositol 1,4,5-triphosphate (PLC/IP 3 )-mediated pathway the release Ca 2 þ from intracellular calcium stores, such as the endoplasmatic reticulum (ER). Astrocytes can also be activated by direct depolarization, which leads to a release of intracellular Ca 2 þ . Calcium is a main player in neuron-astrocyte, intra-astrocyte and inter-astrocyte communication. The gliotransmitters can modulate both pre-and post-synaptic neuronal signaling.
Potential
Similarly, significant clinical improvements in motor function were observed as a result from a DBS lead placement in the subthalamic nucleus (STN) and globus pallidus pars interna of Parkinson patients. 64 The possible involvement of astrocytes in DBS was supported by another recent study in Parkinsonian's rats by Gradinaru et al. 65 Using an optogenetics approach, this group aimed to dissect the Parkinsonian's disease circuitry and the mechanism of DBS in 6-hydroxydopamine-lesioned animals. Astrocytes were specifically targeted with a lentiviral vector that contained an expression cassette of channelrhodopsin-2 driven by the glial fibrillary acidic protein promoter. Stimulation using light resulted in the inhibition of neuronal firing in the STN, which was likely due to astrocytic Ca 2 þ waves that were triggered by the activation of channelrhodopsin. It is important to note that this direct activation of the STN astrocytes was able to inhibit STN neurons, but was not sufficient to reduce the Parkinsonian's symptoms in the rats. These results provide evidence that activation of astrocytes can lead to inhibition of the STN, but it also shows that astrocyte-induced neuronal inhibition by itself is likely not sufficient for the therapeutic effect of DBS in Parkinson's disease.
In summary, these recent data suggest that (1) DBS can activate glia and increase the release of gliaderived transmitters; (2) glial activation may result in acute alterations in local neuronal activity; and (3) glial activation by DBS may have profound effects on network activity patterns.
Reactive astrocytes near stimulation electrode
Several histological studies have shown the occurrence of reactive astrocytes around the implanted electrode. Reactive gliosis is defined by hypertrophy of astrocytes, and an increase in the production of the intermediate filament protein glial fibrillary acidic protein, as well as vimentin, nestin and synemin. 22 In 1979, Stock et al. 66 described that mild reactive gliosis occurred around the track of stimulation electrodes in cats, which were implanted in the rostral hippocampus and amygdala. They report a slight loss of neurons around the tip, and some remnants of micro-bleeding. The leptomeninges at the surface penetration site and the choroid plexus showed a scarred connective tissue reaction, and some giant cells were reported. We have observed similar findings in a majority of brains deposited in the DBS brain tissue network. 67 The first post-mortem study on neuropathological changes induced by electrode implantations in the human STN and thalamic ventral intermediate nucleus was published in 2000. 68 In general, mild reactive astrogliosis was observed near the stimulation electrode. Activated microglia were absent in all cases, but these cells were not carefully examined. Single macrophages, mononuclear leukocytes and multinucleated giant cells were observed in some of the cases. Another study in which the electrode was implanted in the anterior nucleus of the thalamus confirmed these data. 69 In a patient with Parkinson's disease who had 71 months of DBS, Rosenthal fibers (accumulation of aggregated glial fibrillary acidic protein in astrocytes) were observed. 70 A review of the literature up to 2006 reported gliosis in the immediate vicinity of the electrode track in most of the studies. 71 In 2010, a case report was published, in which a post-mortem analysis was performed 12 years after implantation of the electrode in the thalamic ventral intermediate nucleus. As in the other cases, the authors described a small rim of fibrous sheath, and reactive gliosis with some lymphocytic infiltration near the electrodes. 21 In all of these cases, the electrodes had to be removed before the brain was processed for histological analysis. Cells, including reactive astrocytes around the electrode, are likely to adhere to the electrodes during the removal procedure, resulting in an underestimation of the gliotic reaction in the brain. 72 In a study using two Rhesus macaques, chronically implanted electrodes have been reported to cause an increase in reactive astrocytes and microglia. The microglial response in these cases was transient, and was only observed in the brain of the macaque that had an electrode implanted for 3 months. Reactive astrocytes were observed in both macaques at 3 months and 3 years after implantation. 73 A recent study 74 in rats in which electrodes were implanted in the STN revealed a region-dependent effect on neuroinflammation, as measured by in vitro autoradiography with [ 3 H]PK11195, a marker for microglia activity. It is likely that astrocytes are also activated in this study, but this was not addressed. The cortical regions showed more pronounced neuroinflammation than the STN. The implanted rats also showed memory impairment as measured by the novel object recognition task. In a separate study, electrodes were implanted in the hippocampus of rats for a kindling protocol. These experiments revealed that the insertion of electrodes itself induced reactive gliosis. 75 Taken together, mild gliosis around the electrodes in patients, even after chronic implantation (12 years), indicates that DBS induces minor pathology in the brain tissue, and this may support its outstanding safety record. The study in macaques, however, shows that a more extensive reactive gliosis is possible. Furthermore, the recent study in rats 74 suggests that neuroinflammation and memory impairment might occur post-DBS. Therefore, the induction of reactive astrogliosis may modulate local or even more widespread neuronal activity. In an elegant study by Ortinki et al., 76 it was shown that reactive astrocytes had a direct effect on neighboring neurons, which displayed reduced inhibitory synaptic currents. The reactive astrocytes down-regulated glutamine synthetase, leading to a depletion in neuronal gamma-aminobutyric acid and thus a hyper-excitability in the hippocampal circuit. This effect may be dependent on HFS, but in some cases, it is merely induced by the physical presence of the electrode in the brain.
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Neurogenic astrocytes-stimulation of neural precursor proliferation by DBS?
A study by Jeong et al. 77 in a co-culture of neurons and astrocytes on microelectrode arrays demonstrated that electrical stimulation led to migration of neuronal cell bodies, and was enhanced by the presence of astrocytes near stimulating electrodes. This report also provided evidence that electrical stimulation could induce an increase in spontaneous proliferative activity. The authors concluded that increased cell density around the electrode was a result of focal stimulation, and this could be a product of rapid proliferation of progenitor cells that are derived from a sub-population of astrocytes with progenitor cell properties. 25, 26, 78, 79 In a report by Toda et al., 80 it has been shown that HFS of the anterior thalamic nucleus of adult rats produced a two-to threefold increase in the number of neural progenitor cells in the hippocampus, when compared with animals that underwent sham surgeries. Recently, Becker et al. reported that functional electrical stimulation in their rodent model was able to promote the formation of newborn cells in the damaged spinal cord of animals. These authors demonstrated that most new cells expressed markers of neural progenitor and glial cells. 81 In 2010, Encinas et al. 82 reported a twofold increase in the number of BrdU-positive cells in the dentate gyrus of the hippocampus upon HFS of the anterior thalamic nucleus in mice, these data confirm the earlier results in rats. 80 They showed that HFS specifically stimulate the proliferation of the transient amplifying neural progenitors, and that this leads to an increase in new neurons in the granular layer of the dentate gyrus of the hippocampus. 82 HFS has similar effects on these cells as physical exercise 83 or the antidepressant fluoxetine. 84 In a rat 6-hydroxydopamine model for Parkinson's disease, Khaindrava et al. 85 showed that a prolonged HFS of the STN resulted in a significant increase in the survival of newborn neurons in the subventricular zone-rostral migratory stream-olfactory bulb continuum, in the striatum and in the dentate gyrus of the hippocampus. Thus, if proliferation of neural progenitors or neurogenic astrocytes and survival of newborn neurons can be driven by electrical stimulation, DBS could prove to be a novel therapeutic method to treat a broad spectrum of symptoms and diseases.
Conclusion and future directions
In this review, our primary focus was on the role of astrocytes in the working mechanism of DBS. Since astrocytic signaling modulates neuronal networks and DBS is thought to interfere with a pathological activity pattern in a neural network, astrocytes are an important cell type to be investigated. Several papers support the potential role of astrocytes in the mechanism of action of DBS. 43, 65, 86 In summary, we list three possible ways in which glia in general and astrocytes in particular may be involved in the effects of DBS (see Figure 2) . Astrocytes can be triggered by electrical stimulation, change the cerebral blood flow and release ATP and glutamate, both important neuromodulators and regulators of neuronal synaptic networks. Therefore, it is possible that the DBS-induced modulation of network activity is partially due to astrocytic gliotransmission. Another change in gliotransmission may be the observed increase in reactive astrocytes thought to result from the implantation of stimulation Figure 2 Involvement of astrocytes in DBS. Astrocytes can potentially modulate the effect of DBS in several ways and modulate neuronal network activity. The stimulating electrode itself can lead to hypermorphic reactive astrocytes (A), which are likely to affect neuronal signaling. The HFS can act directly on astrocytes resulting in a change in the cerebral blood flow (B) and in the release of gliotransmitters glutamate (Glut) and ATP. Glutamate will stimulate neuronal synaptic release ( þ in right synapse) and ATP is converted by ecto-ATPase into adenosine (ADO) and will silence neuronal communication (À in left synapse) through pre-synaptic inhibition of A1-coupled Ca 2 þ channels and post-synaptic activation of A1-coupled K þ channels. Furthermore, HFS might also induce proliferation of neural precursors, which are an astrocyte subtype (C).
Potential role for glia in DBS effect V Vedam-Mai et al electrodes. Finally, we discuss how HFS increases the proliferation of neurogenic astrocytes, which differentiate into neurons. DBS outcomes have been thus far mainly ascribed to a direct effect on neuronal elements. The growing insight into the role of astrocytes in neuronal communication, and the recent experimental data on a potential role of astrocytes in DBS, asks for an adjustment of the neuronal hypothesis. DBS can either inhibit or stimulate a target area. 31, 33 From an astrocytic point of view, the local inhibitory effect can be explained by a direct stimulation of astrocytes to release ATP, 53, 20 which subsequently leads to an inhibition of synaptic transmission through the action of adenosine on post-and pre-synaptic A1 receptors. 56 On the other hand, release of astrocytic glutamate upon HFS can lead to a local stimulation of synaptic activity. 20 Also, reactive astrocytes, induced by the implantation of the stimulation electrode, can contribute to a stimulation of synaptic activity, as in these cells, the glutamate-glutamine cycle is impaired, leading to synaptic gamma-aminobutyric acid depletion. 76 Due to the propagation of calcium waves in astrocytic networks, 17 the astrocytic effects might spread distant from the stimulation electrode. A clinical effect that might be partly explained by a stimulation of proliferation and neuronal differentiation of neurogenic astrocytes in the hippocampus upon application of HFS to the anterior thalamic nucleus 80, 82, 85 are the changes in mood. 87 We are only now beginning to understand the potential role of astrocytes in the mechanism of action of DBS. To fully grasp the outcome of HFS on the modulation of brain function, both neuronal and astrocytic effects need to be considered. Critical experiments are needed in animal models of DBS, in which HFS is combined with a specific and selective intervention in either astrocytic, or neuronal signaling, or both. A pharmacological approach, for instance, by interfering with receptor function lacks specificity, since some receptors are expressed both in astrocytes and neurons. Therefore, a viral vector approach has to be applied to specifically target astrocytes in a confined brain area with a transgene under control of a cell-type specific, or activitydependent promoter. 88 Another approach would be to develop novel, inducible mouse models, in which either astrocytic communication can be blocked, for instance by targeting gliotransmitters, 89 or intracellular Ca 2 þ . 90 Characterizing the potential role of astrocytes in the working of DBS will provide a more in-depth comprehension of the way it functions to restore normal brain function. This will hopefully enable us continue to enhance DBS technologies so that we can improve surgical outcomes in patients.
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